ERASCA INC. - COMMON STOCK

Erasca Announces Pricing of Underwritten Offering of Common Stock

16 5月 2024 17:00:00 条件 Nasdaq GlobeNewswire

Erasca Reports First Quarter 2024 Business Updates and Financial Results

08 5月 2024 13:01:00 条件 Nasdaq GlobeNewswire

Erasca to Present at the Bank of America Health Care Conference

07 5月 2024 05:00:01 条件 Nasdaq GlobeNewswire

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

24 4月 2024 13:05:00 条件 Nasdaq GlobeNewswire

Erasca Announces $45 Million Oversubscribed Private Placement Financing

27 3月 2024 17:30:00 条件 Nasdaq GlobeNewswire

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

27 3月 2024 13:01:00 条件 Nasdaq GlobeNewswire

Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

14 2月 2024 05:00:00 条件 Nasdaq GlobeNewswire

Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

01 2月 2024 05:00:00 条件 Nasdaq GlobeNewswire

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 1月 2024 05:00:00 条件 Nasdaq GlobeNewswire

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

11 12月 2023 05:00:00 条件 Nasdaq GlobeNewswire

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

09 11月 2023 13:01:00 条件 Nasdaq GlobeNewswire

Erasca to Present at Upcoming Investor Conferences in November

08 11月 2023 05:00:00 条件 Nasdaq GlobeNewswire

Erasca to Present at the Cantor Global Healthcare Conference

19 9月 2023 05:00:01 条件 Nasdaq GlobeNewswire

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

05 9月 2023 05:00:00 条件 Nasdaq GlobeNewswire

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

29 8月 2023 05:00:00 条件 Nasdaq GlobeNewswire

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

10 8月 2023 13:01:00 条件 Nasdaq GlobeNewswire

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

22 6月 2023 13:01:00 条件 Nasdaq GlobeNewswire

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

05 6月 2023 13:01:00 条件 Nasdaq GlobeNewswire

Erasca to Present at Upcoming Investor Conferences

01 6月 2023 05:00:00 条件 Nasdaq GlobeNewswire

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

31 5月 2023 05:00:01 条件 Nasdaq GlobeNewswire